Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.57 |
| ▸ | CA2 | P00918 | 4/20 | 0.57 |
| ▸ | CA12 | O43570 | 3/20 | 0.57 |
| ▸ | CA9 | Q16790 | 3/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13876418 | 1.00 | CA1 (0.57) | CA1CA2CA12CA9CA14 | |
| SCHEMBL1516780 | 1.00 | CA1 (0.57) | CA1CA2CA12CA9CA14 | |
| SCHEMBL28599280 | 1.00 | CA1 (0.57) | CA1CA2CA12CA9CA14 | |
| SCHEMBL4408604 | 0.85 | CA1 (0.66) | CA1CA2CA12CA9CA14 | |
| SCHEMBL14487959 | 0.85 | CA1 (0.59) | CA1CA2CA12CA9CA14 | |
| SCHEMBL84424 | 0.85 | CA1 (0.59) | CA1CA2CA12CA9CA14 | |
| SCHEMBL1765715 | 0.84 | CA1 (0.53) | CA1CA2CA12CA9CA14 | |
| SCHEMBL10610953 | 0.83 | CA1 (0.57) | CA1CA2CA12CA9CA14 | |
| SCHEMBL4640174 | 0.83 | CA1 (0.61) | CA1CA2CA12CA9CA14 | |
| SCHEMBL21147155 | 0.82 | CA1 (0.52) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4629984-A1 | DEVELOPMENT OF POTENT DUAL HDAC/BRD4 INHIBITORS | BioVentures, LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| WO-2025060974-A1 | N-SULFONYL CARBOXAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海宇道生物技术有限公司 | 2025-03-27 | — | — | WO | disclosed |
| WO-2024123929-A1 | DEVELOPMENT OF POTENT DUAL HDAC/BRD4 INHIBITORS | BIOVENTURES, LLC (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20230391812-A1 | RUTHENIUM COMPLEX, PRODUCTION METHOD OF THE COMPLEX, AND PRODUCTION METHOD OF OPTICALLY ACTIVE SECONDARY ALCOHOLS USING THE COMPLEX AS CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-12-07 | — | — | US | disclosed |
| EP-4230603-A1 | RUTHENIUM COMPLEX, METHOD FOR PRODUCING SAID COMPLEX, AND METHOD FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL USING SAID COMPLEX AS CATALYST | Takasago International Corporation (JP) | 2023-08-23 | — | — | EP | disclosed |
| CN-116323522-A | Ruthenium complex, process for producing the same, and process for producing optically active secondary alcohol using the same as catalyst | 高砂香料工业株式会社 | 2023-06-23 | — | — | CN | disclosed |
| EP-3341370-B1 | CGRP RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2021-04-28 | — | — | EP | disclosed |
| CN-107922406-B | CGRP receptor antagonists | 伊兰科美国公司 | 2020-04-03 | — | — | CN | disclosed |
| CN-107922406-A | CGRP receptor antagonist | 伊莱利利公司 | 2018-04-17 | — | — | CN | disclosed |
| US-9637495-B2 | CGRP receptor antagonists | ELI LILLY AND COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637495-B2 | CGRP receptor antagonists | ELI LILLY AND COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637495-B2 | CGRP receptor antagonists | ELI LILLY AND COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170044163-A1 | CGRP RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2017-02-16 | — | — | US | disclosed |
| US-20170044163-A1 | CGRP RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2017-02-16 | — | — | US | disclosed |
| US-20170044163-A1 | CGRP RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2017-02-16 | — | — | US | disclosed |
| WO-2011073487-A1 | PROCEDURE FOR THE ENANTIOSELECTIVE ADDITION OF ORGANOZINC COMPOUNDS TO COMPOUNDS DERIVED FROM ACETOPHENONES | UNIVERSIDAD DE VALLADOLID (ES) | 2011-06-23 | — | — | WO | disclosed |
| US-7612060-B2 | Triazoles and methods of use | AMGEN INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612060-B2 | Triazoles and methods of use | AMGEN INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612060-B2 | Triazoles and methods of use | AMGEN INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20060100213-A1 | Triazoles and methods of use | AMGEN INC. (US) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100213-A1 | Triazoles and methods of use | CYP3A5, CYP3A43, CYP2E1 | CA1 3405/4885CA2 2170/4885CA12 4075/4885 |
| US-20170044163-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CCKBR | CA1 2648/4885CA2 824/4885CA12 1834/4885 |
| US-20230391812-A1 | RUTHENIUM COMPLEX, PRODUCTION METHOD OF THE COMPLEX, AND PRODUCTION METHOD OF OPTICALLY ACTIVE SECONDARY ALCOHOLS USING THE COMPLEX AS CATALYST | ADH5, ADH1A, ADH1C | CA1 2639/4885CA2 2433/4885CA12 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.